– USA. MA – Molecular Loop Biosciences, Inc., a leader in targeted sequencing, announced the addition of Dr. Paul Brown (Ph.D.) to its board of directors today.
About Dr. Paul Brown
Dr. Paul Brown began his career at Roche after completing a post-doctoral fellowship at Caltech in 1986. He held various leadership positions within Roche’s pharmaceutical division, including Lifecycle Leader for Tamiflu® and Xenical® in Switzerland, VP of Sales and Marketing in Canada, and General Manager in Sweden. In 2010, Dr. Brown transitioned to Roche’s Diagnostics Division as President and CEO of Roche Molecular Diagnostics. He grew the division’s core businesses of virology, blood screening, and infectious diseases while enhancing the medical value and testing efficiency in microbiology, oncology, and genomics. Before retiring from Roche at the end of 2020, Dr. Brown was Head of Roche Molecular Solutions, responsible for the company’s Molecular Diagnostics, Tissue Diagnostics, and Sequencing Solutions Business Units worldwide. Since then, he has served in an advisory or board capacity for numerous life science companies.
About Molecular Loop
Molecular Loop tailors customized targeted next-generation sequencing solutions using its unique technology that delivers industry-leading workflow simplicity without sacrificing data quality. The company is leveraging its technology and deep genomic expertise to accelerate life sciences innovations and make personalized healthcare advancements. The team is passionate about making it easier than ever for labs to harness the power of genomic technology and make genetic testing broadly accessible.
For more information: https://molecularloop.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.